Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial.

被引：5

作者：

Motzer, Robert J.

Bex, Axel

Russo, Paul

Tomita, Yoshihiko

Cutuli, Hernan

Rojas, Carlos

Gross-Goupil, Marine

Schinzari, Giovanni

Melichar, Bohuslav

Barthelemy, Philippe

Garcia, Abraham Ruiz

Sosman, Jeffrey A.

Grimm, Marc-Oliver

Goh, Jeffrey C.

Suarez, Cristina

Kollmannsberger, Christian K.

Simsek, Burcin

Spiridigliozzi, Julia

Lee, Chung-Wei

Grunwald, Viktor

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Netherlands Canc Inst, Amsterdam, Netherlands

[3] Niigata Univ, Grad Sch Med & Dent Sci, Niigata, Japan

[4] Hosp Sirio Libanes, Buenos Aires, DF, Argentina

[5] Bradford Hill, Santiago, Chile

[6] Ctr Hosp Univ, Bordeaux, France

[7] Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy

[8] Palacky Univ, Med Sch, Olomouc, Czech Republic

[9] Teaching Hosp, Olomouc, Czech Republic

[10] Inst Cancerol Strasbourg Europe, Strasbourg, France

[11] Hosp 1ro Octubre, Mexico City, DF, Mexico

[12] Northwestern Univ, Med Ctr, Chicago, IL USA

[13] Jena Univ Hosp, Jena, Germany

[14] ICON Res, South Brisbane, Qld, Australia

[15] Hosp Univ Vall dHebron, Vall dHebron Barcelona Hosp Campus, Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[16] Vancouver Canc Ctr, BC Canc, Vancouver, BC, Canada

[17] Bristol Myers Squibb, Princeton, NJ USA

[18] Univ Hosp Essen, West German Canc Ctr Essen, Clin Internal Med Tumor Res, Essen, Germany

[19] Univ Hosp Essen, West German Canc Ctr Essen, Clin Urol, Essen, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期

关键词：

613-225-313; 283-424-3231; 261-566-9263; 613-135-2370-7650-2454; 613-4678-146-485-2759; 613-135-2370-7650-2700; 281-318-5353-2387; 8; 7; 5; 3; 2; 14; 47; 242; 12; 1; 38092-20390;

D O I：

10.1200/JCO.2024.42.4_suppl.LBA358

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：LBA358 / LBA358

页数：1